Biogen Inc. (BIIB)
NASDAQ: BIIB
· Real-Time Price · USD
142.26
-1.40 (-0.97%)
At close: Oct 16, 2025, 3:59 PM
141.50
-0.53%
After-hours: Oct 16, 2025, 07:53 PM EDT
-0.97% (1D)
Bid | 141.82 |
Market Cap | 20.86B |
Revenue (ttm) | 10B |
Net Income (ttm) | 1.53B |
EPS (ttm) | 10.45 |
PE Ratio (ttm) | 13.61 |
Forward PE | 9.18 |
Analyst | Hold |
Dividends | n/a |
Ask | 142.32 |
Volume | 1,422,112 |
Avg. Volume (20D) | 1,735,599.5 |
Open | 144.05 |
Previous Close | 143.66 |
Day's Range | 141.70 - 147.48 |
52-Week Range | 110.04 - 191.19 |
Beta | 0.13 |
Ex-Dividend Date | n/a |
About BIIB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BIIB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BIIB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsBiogen Inc. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+10.09%
Shares of several drugmakers are trading higher af...
Unlock content with
Pro Subscription
3 weeks ago
-0.96%
Biogen shares are trading lower after the FDA issued a Complete Response Letter for the company's sNDA for the high-dose regimen of nusinersen for spinal muscular atrophy.